Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16159)	1/1/2003 7:08:57 PM
From: Edscharp	Read Replies (1) \| Respond to of 17367

Blue, "I am guessing that YOU missed out on that runup to around 17." You're correct. I sure did miss out on that. My hearty congrats to you if you were wise enough to sell near the top. However, would I be remiss if I pointed out that run-up to 17 was based upon hype and not real value of the company? Both Xoma and this thread are enigmas to me. Over the past few years that I've followed Xoma I've been genuinely impressed with the great number of intelligent posters who have posted their wisdom here, most often in an optimistic or supportive manner; and yet, year after year Xoma disappoints everybody. I'm not singling out Xoma per se. With very few exceptions the entire biotech industry has been a disaster for investors. All biotechs including Xoma are nothing more than crap shoots. Seriously, you want to make money on biotechs? Take the next biotech that files it's NDA. Wait for the inevitable run-up in stock price until a week before the FDA advisory meeting; and then short the bejesus out of the company. I'll bet you make serious profit 60%-80% of the time. And, keep in mind that the down side is much larger than the upside. Even if the Advisory committee tentatively approves a drug there are still additional hurdles to face before manufacturing and marketing may begin. So, even with approval there is a dampening effect on the upside share price. Gawd, even drugs that demonstrate sufficient efficacy are often held up by the FDA for additional information or further clinical trials. In today's current climate how can you lose?